CEP44

Across TCGA pan-cancer cohorts, CEP44 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP44 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEP44 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEP44 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where CEP44 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.373	0.951	.002	36	view →
PDAC	DFS	Quartile	III,IV	0.162	0.484	.016	16	view →
CCRCC	DFS	Quartile	II,III,IV	0.830	0.198	.024	6	view →
HNSC	DFS	Tertile	All	0.718	0.338	.047	4	view →
LSCC	OS	Median	All	0.793	1.000	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP44–LUAD (DFS)

Open the LUAD breakdown →